title: [Effectiveness and safety of nadroparin in acute coronary syndrome].
abstract: OBJECTIVE
  To evaluate the effectiveness and safety of subcutaneous low molecular weight heparin (LMWH) used in acute management of patients with non-ST segment elevation acute coronary syndrome (ACS).
  
  
  METHODS
  A total of 102 patients with non-ST segment elevation ACS were treated for at least 48 hours ( > or =5 times) with subcutaneous nadroparin (1 mg/kg each 12 hours). All 102 patients underwent coronary angiographies (CAG) within 8 hours after LMWH injection, followed by immediate percutaneous coronary intervention (PCI).
  
  
  RESULTS
  Anti-Xa activity at the time of catheterization was (0.62 +/- 0.18) IU/ml, and 90% of the patients had anti-Xa activity > 0.5 IU/ml. No death, myocardial infarction relapse or emergent revascularization occurred after PCI. Thrombosis and/or embolism occurred in 2 patients (3.5%) during PCI. Mild hemorrhage was observed in 4 patients (3.9%) of PCI group and in 2 patients (4.4%) in CAG group. No major hemorrhage occurred.
  
  
  CONCLUSIONS
  PCI within 8-12 hours of the last dose after > or =48 hours nadroparin subcutaneous injection seems to be effective and safe.
authors.affiliation: Department of Cardiovascular Center, Beijing Tongren Hospital, Capital University of Medical Sciences, Beijing 100730, China. cardiolucl@yahoo.com.cn
authors.forename: Chang-lin
authors.initials: CL
authors.lastname: Lu
authors.forename: Ru-yang
authors.initials: RY
authors.lastname: Ni
authors.forename: Jin-gang
authors.initials: JG
authors.lastname: Yang
authors.forename: Da-yi
authors.initials: DY
authors.lastname: Hu
authors.forename: Jing-xuan
authors.initials: JX
authors.lastname: Guo
mesh_terms: D054058:Acute Coronary Syndrome / Q000097:blood / Q000628:therapy*; D000800:Angioplasty, Balloon; D000925:Anticoagulants / Q000009:adverse effects / Q000627:therapeutic use*; D065427:Factor Xa Inhibitors; D006801:Humans; D017762:Nadroparin / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D000925:Anticoagulants; D065427:Factor Xa Inhibitors; D017762:Nadroparin